Citigroup Inc. Invests $262,000 in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Citigroup Inc. purchased a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 99,767 shares of the biopharmaceutical company’s stock, valued at approximately $262,000. Citigroup Inc. owned approximately 0.21% of Puma Biotechnology as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PBYI. GSA Capital Partners LLP raised its stake in Puma Biotechnology by 143.8% during the 3rd quarter. GSA Capital Partners LLP now owns 279,629 shares of the biopharmaceutical company’s stock valued at $735,000 after purchasing an additional 164,931 shares during the period. Jump Financial LLC raised its position in Puma Biotechnology by 26.6% during the third quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 5,190 shares during the period. Affinity Asset Advisors LLC lifted its stake in Puma Biotechnology by 14.1% in the 2nd quarter. Affinity Asset Advisors LLC now owns 202,349 shares of the biopharmaceutical company’s stock worth $714,000 after acquiring an additional 25,000 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Puma Biotechnology during the 4th quarter worth about $76,000. Finally, UBS Group AG boosted its position in Puma Biotechnology by 48.8% during the 1st quarter. UBS Group AG now owns 25,985 shares of the biopharmaceutical company’s stock worth $75,000 after acquiring an additional 8,523 shares during the period. Institutional investors and hedge funds own 61.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PBYI. HC Wainwright reduced their price target on shares of Puma Biotechnology from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, March 1st. StockNews.com raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Tuesday, March 12th.

Insider Transactions at Puma Biotechnology

In related news, CEO Alan H. Auerbach sold 41,396 shares of Puma Biotechnology stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $4.49, for a total value of $185,868.04. Following the completion of the sale, the chief executive officer now owns 6,936,947 shares of the company’s stock, valued at approximately $31,146,892.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Puma Biotechnology news, insider Alvin F. Wong sold 7,733 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $4.49, for a total transaction of $34,721.17. Following the transaction, the insider now owns 98,214 shares in the company, valued at $440,980.86. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Alan H. Auerbach sold 41,396 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $4.49, for a total transaction of $185,868.04. Following the completion of the transaction, the chief executive officer now directly owns 6,936,947 shares in the company, valued at approximately $31,146,892.03. The disclosure for this sale can be found here. Insiders have sold a total of 64,811 shares of company stock worth $291,001 in the last 90 days. 22.70% of the stock is owned by insiders.

Puma Biotechnology Stock Performance

Shares of PBYI stock opened at $5.58 on Thursday. Puma Biotechnology, Inc. has a fifty-two week low of $2.13 and a fifty-two week high of $7.73. The stock’s 50-day moving average is $5.56 and its two-hundred day moving average is $4.20. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.57 and a quick ratio of 1.50. The firm has a market cap of $269.01 million, a P/E ratio of 12.13, a PEG ratio of 3.18 and a beta of 1.32.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.07). The firm had revenue of $72.20 million during the quarter, compared to the consensus estimate of $73.22 million. Puma Biotechnology had a net margin of 9.16% and a return on equity of 58.21%. Analysts predict that Puma Biotechnology, Inc. will post 0.29 earnings per share for the current fiscal year.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.